Patents Examined by Brenda Brumback
-
Patent number: 7186407Abstract: Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.Type: GrantFiled: May 14, 2004Date of Patent: March 6, 2007Assignee: Chiron CorporationInventor: Martha Jo Whitehouse
-
Patent number: 7166703Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: April 24, 2002Date of Patent: January 23, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
Patent number: 7166584Abstract: Methods and compounds are disclosed for lowering serum LDL levels or serum cholesterol levels, or for reducing the transport of cholesterol from the gut to the blood or the lymph, based on the observation that a gene known as ABC1 is necessary in order for cholesterol to be transported from the intestinal lumen into the bloodstream. A mutant chicken phenotype, known as the WHAM chicken, characterized by low levels of serum LDL and reduced transport of cholesterol, facilitated the discovery of this function of the ABC1 gene. Techniques which act to inhibit ABC1 activity in the cells of the intestinal wall will result in lower serum cholesterol.Type: GrantFiled: November 1, 2000Date of Patent: January 23, 2007Assignees: Wisconsin Alumni Research Foundation, Xenon Genetics, Inc.Inventors: Alan D. Attie, Mark Cook, Mark P. Gray-Keller, Michael R. Hayden, Simon Pimstone, Angela R. Brooks-Wilson
-
Patent number: 7164007Abstract: Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: August 16, 2002Date of Patent: January 16, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Jean-Philippe F. Stephan, Colin K. Watanabe, William I. Wood
-
Patent number: 7144731Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.Type: GrantFiled: January 28, 2003Date of Patent: December 5, 2006Assignee: Amgen Inc.Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
-
Patent number: 7141652Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: April 24, 2002Date of Patent: November 28, 2006Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
Patent number: 7141390Abstract: The application relates to a newly identified polynucleotide, polypeptide encoded by such polynucleotide, the use of such polynucleotide and polypeptide, as well as the production of such polynucleotide and polypeptide. More particularly, the polypeptide of the present invention is human interleukin-17 receptor like molecule (IL-17RLM).Type: GrantFiled: June 30, 2003Date of Patent: November 28, 2006Assignee: Tsinghua UniversityInventors: Shiqin Xiong, Zhijie Chang, Fu Xinyuan
-
Patent number: 7138494Abstract: Novel sodium-independent small neutral amino acid transporters which transport L- and D-amino acids. A protein comprising the amino acid sequence represented by SEQ ID NO:1 or 4 or an amino acid derived therefrom by deletion, substitution or addition of one or more amino acids and being capable of sodium-independently transporting L- and D-small neutral amino acids and analogs thereof; a gene encoding the above protein; a method of screening substances inhibiting or promoting the function of the above protein; an antibody against the above protein; and a method of regulating cell function by using the above antibody, function inhibitors, function promoters, etc.Type: GrantFiled: August 7, 2002Date of Patent: November 21, 2006Assignee: Japan Science and Technology CorporationInventors: Hitoshi Endou, Yoshikatsu Kanai
-
Patent number: 7135334Abstract: Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: August 16, 2002Date of Patent: November 14, 2006Assignee: Genentech, Inc.Inventors: Kevin P. Baker, Napoleone Ferrara, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Kenneth J. Hillan, Scot A. Marsters, James Pan, Jean-Philippe F. Stephan, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Weilan Ye
-
Patent number: 7135170Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.Type: GrantFiled: October 23, 2003Date of Patent: November 14, 2006Assignee: ZymoGenetics, Inc.Inventors: Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson
-
Patent number: 7129064Abstract: A canine hepatocyte growth factor gene and a 15 base pairs-deleted gene thereof encode a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4 and a protein having an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids and having a canine hepatocyte growth factor activity. The canine hepatocyte growth factor and the 5 amino acids-deleted canine hepatocyte growth factor are useful for the treatment of liver diseases, kidney diseases, lung diseases, digestive diseases, cardiocirculatory diseases or cranial nerve diseases.Type: GrantFiled: June 22, 2001Date of Patent: October 31, 2006Assignee: Nippon Zenyaku Kogyo Ltd.Inventors: Masashi Miyake, Shigehiro Iwabuchi, Yasuyuki Suzuta
-
Patent number: 7122656Abstract: The present invention relates to the field of infection and inflammation and, more specifically, to the field of pathogen-induced nuclear factor kappa B activation. More specifically, a novel splice variant of MyD88, (MyD88S), which has been identified encoding a protein that inhibits LPS-induced NF-?B activation. MyD88S is a target to inhibit the phenomenon of endotoxin-tolerance that occurs in sepsis.Type: GrantFiled: July 9, 2004Date of Patent: October 17, 2006Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Universiteit GentInventors: Rudi Beyaert, Sophie Janssens
-
Patent number: 7122349Abstract: The present invention provides two members of a new family of human proteins, designated as “Zven.” The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes.Type: GrantFiled: November 5, 2004Date of Patent: October 17, 2006Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Paul D. Bishop
-
Patent number: 7105168Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.Type: GrantFiled: June 4, 2003Date of Patent: September 12, 2006Assignee: D. Collen Research Foundation VZWInventors: Peter Carmeliet, Désiré Collen
-
Patent number: 7105159Abstract: This invention provides purified antibodies to the outer membrane domain of prostate-specific membrane (PSM) antigen, compositions of matter comprising PSM antigen antibodies conjugated to a radioisotope or a toxin, and a method of imaging prostate cancer by using PSM antigen antibodies.Type: GrantFiled: June 6, 1995Date of Patent: September 12, 2006Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
-
Patent number: 7097984Abstract: Methods and kits are provided for manipulating and predicting the reproductive capacity of a female subject. The presence of endogenous neurotrophins and addition of exogenous neurotrophins, particularly BDNF, NT-4/5, and NGF, increase the reproductive capacity of a female patient by binding to receptors on the oocytes and stimulating maturation of the oocytes. Administration of antagonists act as a contraceptive because the antagonists prevent the neurotrophins from binding to oocyte receptors. Neurotrophins may also be used to stimulate the maturation of oocyte in vitro.Type: GrantFiled: July 31, 2002Date of Patent: August 29, 2006Assignee: University of Medicine and Dentistry of New JerseyInventors: David B Seifer, Robert Shelden, Bo Feng, Cheryl Dreyfus
-
Patent number: 7091326Abstract: Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) ? subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.Type: GrantFiled: July 17, 2002Date of Patent: August 15, 2006Assignee: Cheil Jedang CorporationInventors: Dong-eok Lee, Myung-suk Oh, Ki-wan Kim, Bo-sup Chung, Ji-sook Park
-
Patent number: 7084246Abstract: The present invention features polypeptides that have at least 90% amino acid identity to wild-type epidermal growth factor, and also have epidermal growth factor biological activity that is greater than the biological activity of wild-type epidermal growth factor.Type: GrantFiled: April 8, 2004Date of Patent: August 1, 2006Assignee: Molecular Logix, Inc.Inventors: Wayne M. Coco, Philip P. Pienkos, A. Katrina Loomis
-
Patent number: 7083933Abstract: This invention relates to the identification of fatty acid or lipid amides that decrease food intake in mammals, including fatty acid ethanolamides, as ligands for the G-protein coupled receptor OSGPR116, and describes the first demonstration of a specific G-protein coupled receptor that is activated by fatty acid ethanolamides that inhibit feeding. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR116, and new pharmaceutical agents identified by these methods. It is also directed to the use of such agents in the manufacture of medicaments for the treatment of OSGPR116 mediated diseases, and methods of treating diseases such as obesity and diabetes by administering to an individual a therapeutic amount of a modulator of OSGPR116 identified by these methods.Type: GrantFiled: May 6, 2004Date of Patent: August 1, 2006Assignee: Prosidion LimitedInventor: Graeme Griffin
-
Patent number: 7081240Abstract: A protein mixture that is useful in the treatment of wounds, where the mixture is isolated from bone or is produced from recombinant proteins and may include two or more of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, TGF-?1, TGF-?2, TGF-?3, and FGF-1.Type: GrantFiled: June 28, 2000Date of Patent: July 25, 2006Assignee: Zimmer OrthoBioLogics, Inc.Inventors: Rama Akella, John P. Ranieri